Literature DB >> 27153353

Self-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotype.

Roberto Ravasio1, Elena Ceccacci2, Saverio Minucci3.   

Abstract

Among the functional subpopulations that coexist within the tumor, 'cancer stem cells' are characterized by increased self-renewal and the ability to derive all of the other subpopulations of tumor cells ('bulk'). The functional heterogeneity among cancer stem cells and bulk cells must reflect distinct cellular epigenetic landscapes, but - due to the difficulty to isolate bona fide cancer stem cells with a high degree of purity - those different epigenetic landscapes, and the molecular mechanisms underlying them, remain largely unknown. Cues of intratumor phenotypic plasticity complicate the interpretation of the cancer stem cell phenotype: we contend that, however, the concept of cancer stem cell has crucial therapeutic implication, and remains a key target for the exploration of the cancer epigenome.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27153353     DOI: 10.1016/j.gde.2016.04.002

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  9 in total

1.  OleD Loki as a Catalyst for Hydroxamate Glycosylation.

Authors:  Ryan R Hughes; Khaled A Shaaban; Larissa V Ponomareva; Jamie Horn; Chunhui Zhang; Chang-Guo Zhan; S Randal Voss; Markos Leggas; Jon S Thorson
Journal:  Chembiochem       Date:  2019-11-26       Impact factor: 3.164

Review 2.  Heterogeneity of tumor cells in terms of cancer-initiating cells.

Authors:  Eiichi Morii
Journal:  J Toxicol Pathol       Date:  2016-09-25       Impact factor: 1.628

3.  Novel silk fibroin nanoparticles incorporated silk fibroin hydrogel for inhibition of cancer stem cells and tumor growth.

Authors:  Puyuan Wu; Qin Liu; Qin Wang; Hanqing Qian; Lixia Yu; Baorui Liu; Rutian Li
Journal:  Int J Nanomedicine       Date:  2018-09-17

4.  let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer.

Authors:  Jun Yin; Weimin Hu; Lei Pan; Wenfan Fu; Lu Dai; Zeyong Jiang; Feng Zhang; Jian Zhao
Journal:  Oncol Rep       Date:  2019-06-12       Impact factor: 3.906

Review 5.  Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer.

Authors:  Logeswari Ponnusamy; Prathap Kumar S Mahalingaiah; Yu-Wei Chang; Kamaleshwar P Singh
Journal:  Cancer Drug Resist       Date:  2019-06-19

6.  Potential molecular mechanism in self-renewal is associated with miRNA dysregulation in sacral chordoma - A next-generation RNA sequencing study.

Authors:  Arpad Bozsodi; Beata Scholtz; Gergo Papp; Zoltan Sapi; Adam Biczo; Peter Pal Varga; Aron Lazary
Journal:  Heliyon       Date:  2022-08-13

Review 7.  The viable circulating tumor cells with cancer stem cells feature, where is the way out?

Authors:  Y T Luo; J Cheng; X Feng; S J He; Y W Wang; Q Huang
Journal:  J Exp Clin Cancer Res       Date:  2018-02-26

8.  Lung CSC-derived exosomal miR-210-3p contributes to a pro-metastatic phenotype in lung cancer by targeting FGFRL1.

Authors:  Li Wang; Jun He; Haoyue Hu; Li Tu; Zhen Sun; Yanyang Liu; Feng Luo
Journal:  J Cell Mol Med       Date:  2020-05-12       Impact factor: 5.310

9.  lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.

Authors:  Gongcai Qiu; Donglai Ma; Fujun Li; Dongsheng Sun; Zhaolin Zeng
Journal:  Int J Oncol       Date:  2019-05-06       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.